PPARA and metabolic dysfunction-associated steatohepatitis: Furthermore, it accurately recapitulates the anti-steatotic and anti-fibrotic properties of elafibranor, a PPARα/δ inhibitor currently in phase 3 clinical trials for NASH, therefore demonstrating its predictive value [17].